Dizal Pharma receives US$100 million in Series A financing

2020-08-23
|
ChinaMedical

Dizal Pharma receives US$100 million in Series A financing

Recently, Dizal Pharma announced the completion of a US$100 million Series A financing for the research and development of small molecules.


This round was led by Lilly Asia Ventures.


Sequoia Capital, Trinity Innovation Fund and other internationally renowned biomedical funds participated in the investment and received strategic support from Wuxi's government fund.


Dizal Pharma decided to establish a China headquarters in Wuxi High-tech Zone, and invest in the establishment of R&D, operation, production, sales and distribution centers in stages.


It will actively create a cutting-edge, practical and characteristic innovative drug ecosystem, attracting partners from the R&D, capital, and industrial circles, and jointly promote the development of innovative drugs in Wuxi and even China.



RELATED ARTICLES

Eugenlight Technologies closes Series A of RMB tens of millions
2020-09-13
|
PEVC , Semiconductor , Electroinic

Microtera Semiconductor closes Series A with RMB tens of millions
2020-09-13
|
PEVC , Semiconductor

Vertex Ventures completes new fund raising of RMB three bln
2020-09-13
|
PEVC , Technology , Semiconductor

Best Compound closes Pre-A with RMB of 100 million led by CTC Capital
2020-09-09
|
PEVC , Semiconductor

Reactor Microelectronics closes Series B for high-speed power integration chips
2020-09-08
|
Semiconductor , Electronic , PEVC

VisionX closes Series A led by Sequoia Capital
2020-08-14
|
PEVC , Medical care

Lupeng Pharmaceutical closes RMB170m Series A+ round led by Lilly Asia Ventures
2020-06-25
|
Pharmaceutical , PEVC

Miaoshou Doctor closes RMB600m Series D1 round
2020-06-17
|
PEVC , Medical care

Pano.video nets RMB25m in angel round led by Sequoia Capital
2020-06-17
|
PaaS , Cloud computing , PEVC

BYD Semiconductor completes a capital increase of 1.9 billion yuan
2020-05-26
|
Automotive , Semiconductor
China SDG